An oral bisphosphonate may slow the development of symptomatic bone metastases and reduce the risk of death from this disease, new data show.
FDA approves cefepime/enmetazobactam for complicated UTI
The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.
Dr. Malik evaluates quality of Reddit content on recurrent UTIs
“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.
FDA requests additional data regarding cefepime-taniborbactam for cUTI
The FDA has issued a complete response letter regarding a new drug application for cefepime-taniborbactam for the treatment of patients with complicated urinary tract infection.
Destigmatizing Urology: Dr. Blaivas discusses vaginal mesh surgery
“To me, the overwhelming thing is understanding that treatments are, by and large, effective,” says Jerry G. Blaivas, MD, FACS.
Published data show superiority of cefepime–taniborbactam over meropenem for cUTI
Cefepime-taniborbactam is currently under review by the FDA for cUTI, including acute pyelonephritis, based on data from the CERTAIN-1 trial.
AUGS Position Statement: Vaginal Pessary Use and Management for Pelvic Organ Prolapse
The purpose of this clinical consensus statement is to identify areas of expert consensus and nonconsensus regarding pessary fitting, follow-up, and management of pessary complications to improve the safety and quality of care where evidence is currently limited.
2 Commerce Drive Cranbury, NJ 08512